Childhood acute lymphoblastic leukemia
Relapsed and refractory disease after frontline cure rates: blinatumomab, inotuzumab and CD19 CAR-T cells.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 1 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for childhood acute lymphoblastic leukemia on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 5 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Clinical |
|---|---|---|---|---|
| ARID5B AT-rich interaction domain 5B | 0.33 | 0.54 | – | |
| KITPeds RMTL KIT proto-oncogene, receptor tyrosine kinase | 0.30 | – | – | |
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.30 | – | – | |
| ABL1Peds RMTL ABL proto-oncogene 1, non-receptor tyrosine kinase | 0.30 | – | – | |
| BCR BCR activator of RhoGEF and GTPase | 0.30 | – | – | |
| TOP2A DNA topoisomerase II alpha | 0.27 | – | – | |
| MS4A1Peds RMTL membrane spanning 4-domains A1 | 0.26 | – | – | |
| NR3C1 nuclear receptor subfamily 3 group C member 1 | 0.25 | – | – | |
| PRIM2 DNA primase subunit 2 | 0.24 | – | – | |
| POLD2 DNA polymerase delta 2, accessory subunit | 0.24 | – | – | |
| POLD4 DNA polymerase delta 4, accessory subunit | 0.24 | – | – | |
| POLA2 DNA polymerase alpha 2, accessory subunit | 0.24 | – | – | |
| POLE3 DNA polymerase epsilon 3, accessory subunit | 0.24 | – | – | |
| POLA1 DNA polymerase alpha 1, catalytic subunit | 0.24 | – | – | |
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.24 | – | – | |
| PRIM1 DNA primase subunit 1 | 0.24 | – | – | |
| POLE2 DNA polymerase epsilon 2, accessory subunit | 0.24 | – | – | |
| POLD3 DNA polymerase delta 3, accessory subunit | 0.24 | – | – | |
| POLE DNA polymerase epsilon, catalytic subunit | 0.24 | – | – | |
| CD3D CD3 delta subunit of T-cell receptor complex | 0.20 | – | – | |
| CD3E CD3 epsilon subunit of T-cell receptor complex | 0.20 | – | – | |
| CD3G CD3 gamma subunit of T-cell receptor complex | 0.20 | – | – | |
| CD19Peds RMTL CD19 molecule | 0.20 | – | – | |
| TUBB2B tubulin beta 2B class IIb | 0.20 | – | – | |
| TUBA1C tubulin alpha 1c | 0.20 | – | – | |
| TUBB tubulin beta class I | 0.20 | – | – | |
| TUBB3 tubulin beta 3 class III | 0.20 | – | – | |
| TUBB8 tubulin beta 8 class VIII | 0.20 | – | – | |
| TUBA3C tubulin alpha 3c | 0.20 | – | – | |
| TUBB2A tubulin beta 2A class IIa | 0.20 | – | – | |
| TOP2B DNA topoisomerase II beta | 0.20 | – | – | |
| TUBB4A tubulin beta 4A class IVa | 0.20 | – | – | |
| TUBB4B tubulin beta 4B class IVb | 0.20 | – | – | |
| TUBB6 tubulin beta 6 class V | 0.20 | – | – | |
| TUBA3E tubulin alpha 3e | 0.20 | – | – | |
| DHFR dihydrofolate reductase | 0.20 | – | – | |
| TUBA1B tubulin alpha 1b | 0.20 | – | – | |
| TUBA1A tubulin alpha 1a | 0.20 | – | – | |
| TUBB1 tubulin beta 1 class VI | 0.20 | – | – | |
| TUBA4A tubulin alpha 4a | 0.20 | – | – | |
| PSMB7 proteasome 20S subunit beta 7 | 0.18 | – | – | |
| PPAT phosphoribosyl pyrophosphate amidotransferase | 0.18 | – | – | |
| PSMB5 proteasome 20S subunit beta 5 | 0.18 | – | – | |
| LCK LCK proto-oncogene, Src family tyrosine kinase | 0.18 | – | – | |
| PSMC2 proteasome 26S subunit, ATPase 2 | 0.18 | – | – | |
| PSMD2 proteasome 26S subunit ubiquitin receptor, non-ATPase 2 | 0.18 | – | – | |
| RRM2B ribonucleotide reductase regulatory TP53 inducible subunit M2B | 0.18 | – | – | |
| FYN FYN proto-oncogene, Src family tyrosine kinase | 0.18 | – | – | |
| PSMB3 proteasome 20S subunit beta 3 | 0.18 | – | – | |
| RRM2 ribonucleotide reductase regulatory subunit M2 | 0.18 | – | – |
18 biomarkers in Childhood acute lymphoblastic leukemia have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “B-lymphoblastic Leukemia/lymphoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 167 accepted items exist; the first 100 were read. This is the published evidence, not treatment advice.
- IKZF1 Deletion level A
- ETV6::RUNX1 Fusion level A
- TCF3::PBX1 Fusion level A
- v::JAK2 Fusion level A
- BCR::ABL1 Fusion level B
- TCF3::HLF Fusion level B
- TP53 Mutation level B
- EPOR rearrangements level B
- ETV6::ABL1 Fusion level B
- IGH::CRLF2 Fusion level B
- IGH::EPOR Fusion level B
- IGH::IL3 Fusion level B